trial

Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy

NCTId NCT01677377
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 45 (actual)
Sponsored by Indivior Inc.
Primary completion 2013-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
45 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Factorial
Masking
None
Start
2012-08
Primary completion
2013-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
RisperidoneRBP-7000

Sponsors

Indivior Inc.Lead Sponsor

Investigators

2
Philippa Whitelaw, Sr. Dir of Proj DeliverStudy Director
Ashley Huston, PMPStudy Director

Sites

2 total
Little Rock, United StatesLong Beach, United States

Linked catalysts

1
Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Effic — primary completion2013-04

Facts & assertions

4 sourced
Enrollment
45
Phase
PHASE2
Primary Completion Date
2013-04
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
RBP-7000
drug
lead_sponsor
Indivior Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Philippa Whitelaw, Sr. Dir of Proj Deliver
person
Ashley Huston, PMP
person